COVID-19患者血栓栓塞风险管理需求
炎症过程、细胞因子风暴和肺损伤可增加血栓形成风险,但血栓事件总发生率尚不确定。重症及高龄、男性、肥胖、癌症、合并症和入住ICU者风险更高,目前缺乏国际管理指南。
要点
- COVID-19相关炎症和细胞因子风暴增加血栓风险。
- 重症及高龄、男性、肥胖、癌症、合并症、ICU患者风险更高。
- 国际指南缺乏COVID-19患者血栓风险管理建议。
核心结论
- COVID-19患者血栓栓塞风险增加,但总发生率不确定,需关注风险管理。
研究设计与样本
- 本文为综述,探讨COVID-19患者血栓形成证据与理论并反思本中心经验。
主要发现
- COVID-19相关炎症过程、细胞因子风暴和肺损伤可增加血栓形成风险。
- 重症及高龄、男性、肥胖、癌症、合并症和入住ICU患者血栓事件风险更高。
临床怎么用
- 临床应关注COVID-19患者血栓风险,尤其重症及具有高危因素者。
局限性
- 血栓事件总发生率尚不确定,且缺乏国际管理指南。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
COVID-19 first appeared in Wuhan, Hubei Province, China, in December 2019. Thought to be of zoonotic origin, it has been named SARS-CoV-2 (COVID-19) and has spread rapidly. As of April 20, 2020, there have been >2.4 million cases recorded worldwide. The inflammatory process, cytokine storm, and lung injury that are associated with COVID-19 can put patients at an increased risk of thrombosis. The total incidence of thrombotic events in COVID-19 patients is currently uncertain. Those with more severe disease and with other risk factors, including increasing age, male sex, obesity, cancer, comorbidities, and intensive care unit admission, are at higher risk of these events. However, there is little international guidance on managing these risks in COVID-19 patients. In this paper, we explore the current evidence and theories surrounding thrombosis in these unique patients and reflect on experience from our center.
引用
- Khan IH, Savarimuthu S, Leung MST, et al. The need to manage the risk of thromboembolism in COVID-19 patients. J Vasc Surg. 2020. PMID: 32417304. doi:10.1016/j.jvs.2020.05.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。